Dr. Ira Kirschenbaum, a leading orthopedic surgeon, says that obesity is one of the main causes of people’s knees and hips breaking down at younger ages than they had in the past. He points to a study that the American Academy of Orthopaedic Surgeon recently conducted. The average age of people who need these types of surgeries dropped to 65 from 66 in just one year.
He is the director of orthopeadics at Bronxcare Health System. Dr. Ira Kirschenbaum regularly performs knee and joint replacement surgery in addition to shoulder surgery. He says that just 10 pounds of weight can cause a lot of damage to joints. Every excess pound a person weight puts an extra four pounds of pressure on their knees and hips. Their joints are compressed too much which causes the cartilage and other soft tissues to wear away leading to surgery.
He gives people an experiment to try. Dr. Ira Kirschenbaum says to pick up something weighing 10 pounds and walk around with it. Notice the feeling in your knees and feel how there is extra pressure on them. This is why after people lose some weight they will say they, “Feel so light on my feet”.
Dr. Ira Kirschenbaum says that surgery doesn’t always need to be the answer, though, and he will often recommend other interventions. This can include eating a better diet, getting more exercise, or doing specific exercise to help joints. He will also sometime recommend to his patients that they change their work habits.
He is a nationally recognized expert when it comes to orthopedics. Dr. Ira Kirschenbaum has been an orthopedic surgeon since 1991. Additionally, he lectures on this subject at medical schools. He is also very involved in other industries such as information technology.
Book an appointment to see Dr. Ira here https://www.md.com/doctor/ira-h-kirschenbaum-md
JeanMarie Guenot is a distinguished business executive who has made an excellent career for herself. With years of experience and a deep understanding of oncology, cardiovascular and neurology, and excellent leadership skills makes her one of the best in her industry. She has also worked in research and development companies, corporate companies in both the private and public sector. Guenot has led various companies in the health sector in greatness using her brilliance leadership.
Being the current president and chief executive officer at Amphivena she has made a great impact towards the company. Amphivena Pharmaceuticals deals in the development of bifunctional antibodies that are useful in the treatment of hematologic malignancies. As the leader, she has led the company into a contract agreement with Janssen Biotech, to research undisclosed tumor antigen to patients. Moreover, the success of the company’s models to treat diseases have been attributed to her as the leader and also to having the know how necessary for the projects.
Jeanmarie Guenot has worked at various other firms at executive positions. At Hoffman-La Roche, she provided advice and counsel for the company plants at both Shangai and Basel. She led the company in negotiations for mergers and acquisitions. She also led the company towards various clinical investigations for the treatment of autoimmune diseases, an $800 million venture. She is also vastly known for her role in the licensing of Ophthotech, a drug used in the treatment of cancer.
Guenot is not new to social media. She uses the platform to enlighten her followers on the findings her company has been able to come up with. On Facebook she states that she began at Atlas Venture, where she had the role of managing capital investments for the company. She has training in chemistry and medicine. She states that her career experiences have helped shape her and his she leads her company.
Dr JeanMarie Guenot is one of the few passionate and exemplary leaders who have dedicated their career and lives at helping others and transforming the society through their work. She sets a perfect example for people who which to make a change to the world.
Read about how she’s trying to change the world now, with her partnership with Takeda: https://www.takeda.com/news/2017/20170111_7659.html